Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus

Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus Overview   In the management of mild to moderate myasthenia gravis (MG), the utilization of tacrolimus is typically reserved for cases that do not respond to glucocorticoids. This study sought to assess the potential advantages of mono-tacrolimus over mono-glucocorticoids in treating MG patients. The primary endpoint

Rheumatoid Arthritis Work Limitation Factors

Rheumatoid Arthritis Work Limitation Factors Rheumatic and musculoskeletal diseases (RMD) introduce pain and functional limitations into the workplace, affecting individuals with rheumatoid arthritis and osteoarthritis. This study delves into the multifaceted factors that shape the work challenges arising from RMD, acknowledging the broader societal costs involved. By shedding light on these

Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus